Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893003 | 0.87 | MAPT (0.57) | EGFRMAPTMAPK1AHRHTT | |
| SCHEMBL4890852 | 0.83 | EGFR (0.55) | EGFRMAPTMAPK1AHRHTT | |
| SCHEMBL4007231 | 0.82 | MAPT (0.78) | EGFRMAPTMAPK1AHRHTT | |
| SCHEMBL4890620 | 0.77 | EGFR (0.71) | EGFRMAPTMAPK1AHRHTT | |
| SCHEMBL1733817 | 0.76 | EGFR (0.60) | EGFRMAPTMAPK1ABCG2CLK1 | |
| SCHEMBL4931410 | 0.76 | MAPT (0.66) | EGFRMAPTMAPK1AHRHTT | |
| Hydrochloric Acid SCHEMBL6180313 | 0.76 | EGFR (0.70) | EGFRMAPTMAPK1AHRHTT | |
| SCHEMBL28469600 | 0.74 | MAPT (0.80) | EGFRMAPTMAPK1HTTKDR | |
| SCHEMBL4935871 | 0.74 | RAF1 (0.64) | EGFRMAPTMAPK1AHRHTT | |
| SCHEMBL28798385 | 0.73 | EGFR (0.56) | EGFRABCG2CLK1EPHA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | ARROW THERAPEUTICS LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1748991-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105761-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311076-A1 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents | EIF2AK2, MAVS, IRF3 | EGFR 3952/4885MAPT 2064/4885MAPK1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.